In 2021, digital therapeutics benefited from record-breaking investment, up 134 percent from the previous year and topping out at nearly $9 billion. In 2023, however, the poster child of digital therapeutics, with multiple FDA-approved products, filed for Chapter 11 bankruptcy protection, leaving investors wondering what the future holds. Is this a bellwether for future challenges facing the industry, or an opportunity to rethink how digital-native products can be distributed and reimbursed? Panelists will examine whether FDA approval should be encouraged for products in the digital space and if there are viable reimbursement models for these solutions. Finally, panelists will discuss the potential value of evidence-based digital health and the advantages digital-native products may have over their conventional counterparts.  

Moderator

Tina Reed

Senior Health Care Reporter, Axios

Speakers

Robert DeLuca

President, Orexo Pharmaceuticals

Arun Gupta

CEO, Big Health

Julia Hu

CEO and Co-Founder, Lark Health

Matthew Stoudt

CEO, AppliedVR, Inc.

Troy Tazbaz

Director, Digital Health Center of Excellence, US Food and Drug Administration